Review



antibody targeting trim28  (Proteintech)


Bioz Verified Symbol Proteintech is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 88
      Buy from Supplier

    Structured Review

    Proteintech antibody targeting trim28
    Figure 1. <t>TRIM28</t> expression is elevated in cervical cancer tissues and cell lines. (A) Analysis from the Oncomine database showing that TRIM28 mRNA expression is significantly elevated in cervical cancer tissues (n=40) compared with that in normal tissues (n=5). The data were obtained from a previous study (35). (B) TRIM28 mRNA levels in 20 paired cervical cancer samples and adjacent normal tissues examined by qRT‑PCR. (C) Immunohistochemical staining of normal and cervical cancer tissues with anti-TRIM28 antibody. The expression levels of TRIM28 in human cervical cancer cells and normal human cervical tissues were measured by qRT‑PCR (D) and western blotting (E). Data are presented as means ± SD. *P<0.05.
    Antibody Targeting Trim28, supplied by Proteintech, used in various techniques. Bioz Stars score: 88/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/antibody+targeting+trim28/CL594-conjugated+KAP1+Antibody/pm29393469-36-23-26
    Average 88 stars, based on 2 article reviews
    antibody targeting trim28 - by Bioz Stars, 2026-11
    88/100 stars

    Images

    1) Product Images from "TRIM28 promotes cervical cancer growth through the mTOR signaling pathway."

    Article Title: TRIM28 promotes cervical cancer growth through the mTOR signaling pathway.

    Journal: Oncology reports

    doi: 10.3892/or.2018.6235

    Figure 1. TRIM28 expression is elevated in cervical cancer tissues and cell lines. (A) Analysis from the Oncomine database showing that TRIM28 mRNA expression is significantly elevated in cervical cancer tissues (n=40) compared with that in normal tissues (n=5). The data were obtained from a previous study (35). (B) TRIM28 mRNA levels in 20 paired cervical cancer samples and adjacent normal tissues examined by qRT‑PCR. (C) Immunohistochemical staining of normal and cervical cancer tissues with anti-TRIM28 antibody. The expression levels of TRIM28 in human cervical cancer cells and normal human cervical tissues were measured by qRT‑PCR (D) and western blotting (E). Data are presented as means ± SD. *P<0.05.
    Figure Legend Snippet: Figure 1. TRIM28 expression is elevated in cervical cancer tissues and cell lines. (A) Analysis from the Oncomine database showing that TRIM28 mRNA expression is significantly elevated in cervical cancer tissues (n=40) compared with that in normal tissues (n=5). The data were obtained from a previous study (35). (B) TRIM28 mRNA levels in 20 paired cervical cancer samples and adjacent normal tissues examined by qRT‑PCR. (C) Immunohistochemical staining of normal and cervical cancer tissues with anti-TRIM28 antibody. The expression levels of TRIM28 in human cervical cancer cells and normal human cervical tissues were measured by qRT‑PCR (D) and western blotting (E). Data are presented as means ± SD. *P<0.05.

    Techniques Used: Expressing, Immunohistochemical staining, Staining, Western Blot

    Figure 3. TRIM28 enhances cervical cancer cell tumorigenicity. (A) Tumor volumes were measured on the indicated days. (B) At the end of the experiment, the weights were measured. (C) The proliferation index (right) was determined based on the percentage of Ki67-positive cells (left). (D) Western blot analysis of TRIM28 and p-mTOR protein expression in indicated tumor xenografts. Data are presented as means ± SD. *P<0.05.
    Figure Legend Snippet: Figure 3. TRIM28 enhances cervical cancer cell tumorigenicity. (A) Tumor volumes were measured on the indicated days. (B) At the end of the experiment, the weights were measured. (C) The proliferation index (right) was determined based on the percentage of Ki67-positive cells (left). (D) Western blot analysis of TRIM28 and p-mTOR protein expression in indicated tumor xenografts. Data are presented as means ± SD. *P<0.05.

    Techniques Used: Western Blot, Expressing

    Figure 2. TRIM28 promotes cervical cancer cell proliferation by accelerating the cell cycle. (A) Western blot analysis of TRIM28 protein expression in TRIM28-infected cells and TRIM28 shRNA-infected cells. GAPDH was used as the loading control. (B) Effects of TRIM28 upregulation or downregulation on the proliferation of SiHa or CaSki cells analyzed by the MTT assay. (C) Representative micrographs (left) and quantification (right) of colonies formed by the indicated cervical cancer cell lines. (D) Cell cycle progression of the indicated cervical cancer cell lines analyzed by flow cytometry. (E) Representative images (left) and quantification (right) of BrdU-positive cells in the indicated cervical cancer cell lines. Data are presented as means ± SD. *P<0.05.
    Figure Legend Snippet: Figure 2. TRIM28 promotes cervical cancer cell proliferation by accelerating the cell cycle. (A) Western blot analysis of TRIM28 protein expression in TRIM28-infected cells and TRIM28 shRNA-infected cells. GAPDH was used as the loading control. (B) Effects of TRIM28 upregulation or downregulation on the proliferation of SiHa or CaSki cells analyzed by the MTT assay. (C) Representative micrographs (left) and quantification (right) of colonies formed by the indicated cervical cancer cell lines. (D) Cell cycle progression of the indicated cervical cancer cell lines analyzed by flow cytometry. (E) Representative images (left) and quantification (right) of BrdU-positive cells in the indicated cervical cancer cell lines. Data are presented as means ± SD. *P<0.05.

    Techniques Used: Western Blot, Expressing, Infection, shRNA, Control, MTT Assay, Flow Cytometry

    Figure 4. TRIM28 promotes cervical cancer cell proliferation via the mTOR signaling pathway. (A) Western blot analysis of TRIM28, p-mTOR(S2448), mTOR, p-S6K1(T389), and S6K1 in TRIM28 shRNA-infected CaSki cells and TRIM28-infected SiHa cells in the presence or absence of 20 nM evero- limus (EVE) for 48 h. GAPDH served as the loading control. (B-D) Cell proliferation, cell cycle, and BrdU incorporation were analyzed in TRIM28-infected SiHa cells in the presence or absence of EVE for 48 h. Data are presented as means ± SD. *P<0.05.
    Figure Legend Snippet: Figure 4. TRIM28 promotes cervical cancer cell proliferation via the mTOR signaling pathway. (A) Western blot analysis of TRIM28, p-mTOR(S2448), mTOR, p-S6K1(T389), and S6K1 in TRIM28 shRNA-infected CaSki cells and TRIM28-infected SiHa cells in the presence or absence of 20 nM evero- limus (EVE) for 48 h. GAPDH served as the loading control. (B-D) Cell proliferation, cell cycle, and BrdU incorporation were analyzed in TRIM28-infected SiHa cells in the presence or absence of EVE for 48 h. Data are presented as means ± SD. *P<0.05.

    Techniques Used: Western Blot, shRNA, Infection, Control, BrdU Incorporation Assay

    Related Articles

    Blocking Assay:

    Article Title: TRIM28 promotes cervical cancer growth through the mTOR signaling pathway.
    Article Snippet: .. After blocking the endogenous peroxidase with 3% hydrogen peroxide, the sections were washed with Tris-buffered saline (TBS) and then incubated with a primary antibody targeting TRIM28 (Proteintech, Hubei, China) for 1 h at 37 ̊C. ..

    Saline:

    Article Title: TRIM28 promotes cervical cancer growth through the mTOR signaling pathway.
    Article Snippet: .. After blocking the endogenous peroxidase with 3% hydrogen peroxide, the sections were washed with Tris-buffered saline (TBS) and then incubated with a primary antibody targeting TRIM28 (Proteintech, Hubei, China) for 1 h at 37 ̊C. ..

    Incubation:

    Article Title: TRIM28 promotes cervical cancer growth through the mTOR signaling pathway.
    Article Snippet: .. After blocking the endogenous peroxidase with 3% hydrogen peroxide, the sections were washed with Tris-buffered saline (TBS) and then incubated with a primary antibody targeting TRIM28 (Proteintech, Hubei, China) for 1 h at 37 ̊C. ..



    Similar Products

    antibody targeting trim28  (Proteintech)
    88
    Proteintech antibody targeting trim28
    Figure 1. <t>TRIM28</t> expression is elevated in cervical cancer tissues and cell lines. (A) Analysis from the Oncomine database showing that TRIM28 mRNA expression is significantly elevated in cervical cancer tissues (n=40) compared with that in normal tissues (n=5). The data were obtained from a previous study (35). (B) TRIM28 mRNA levels in 20 paired cervical cancer samples and adjacent normal tissues examined by qRT‑PCR. (C) Immunohistochemical staining of normal and cervical cancer tissues with anti-TRIM28 antibody. The expression levels of TRIM28 in human cervical cancer cells and normal human cervical tissues were measured by qRT‑PCR (D) and western blotting (E). Data are presented as means ± SD. *P<0.05.
    Antibody Targeting Trim28, supplied by Proteintech, used in various techniques. Bioz Stars score: 88/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/antibody+targeting+trim28/CL594-conjugated+KAP1+Antibody/pm29393469-36-23-26
    Average 88 stars, based on 1 article reviews
    antibody targeting trim28 - by Bioz Stars, 2026-11
    88/100 stars
    		  Buy from Supplier

    Image Search Results


    Figure 1. TRIM28 expression is elevated in cervical cancer tissues and cell lines. (A) Analysis from the Oncomine database showing that TRIM28 mRNA expression is significantly elevated in cervical cancer tissues (n=40) compared with that in normal tissues (n=5). The data were obtained from a previous study (35). (B) TRIM28 mRNA levels in 20 paired cervical cancer samples and adjacent normal tissues examined by qRT‑PCR. (C) Immunohistochemical staining of normal and cervical cancer tissues with anti-TRIM28 antibody. The expression levels of TRIM28 in human cervical cancer cells and normal human cervical tissues were measured by qRT‑PCR (D) and western blotting (E). Data are presented as means ± SD. *P<0.05.

    Journal: Oncology reports

    Article Title: TRIM28 promotes cervical cancer growth through the mTOR signaling pathway.

    doi: 10.3892/or.2018.6235

    Figure Lengend Snippet: Figure 1. TRIM28 expression is elevated in cervical cancer tissues and cell lines. (A) Analysis from the Oncomine database showing that TRIM28 mRNA expression is significantly elevated in cervical cancer tissues (n=40) compared with that in normal tissues (n=5). The data were obtained from a previous study (35). (B) TRIM28 mRNA levels in 20 paired cervical cancer samples and adjacent normal tissues examined by qRT‑PCR. (C) Immunohistochemical staining of normal and cervical cancer tissues with anti-TRIM28 antibody. The expression levels of TRIM28 in human cervical cancer cells and normal human cervical tissues were measured by qRT‑PCR (D) and western blotting (E). Data are presented as means ± SD. *P<0.05.

    Article Snippet: After blocking the endogenous peroxidase with 3% hydrogen peroxide, the sections were washed with Tris-buffered saline (TBS) and then incubated with a primary antibody targeting TRIM28 (Proteintech, Hubei, China) for 1 h at 37 ̊C.

    Techniques: Expressing, Immunohistochemical staining, Staining, Western Blot

    Figure 3. TRIM28 enhances cervical cancer cell tumorigenicity. (A) Tumor volumes were measured on the indicated days. (B) At the end of the experiment, the weights were measured. (C) The proliferation index (right) was determined based on the percentage of Ki67-positive cells (left). (D) Western blot analysis of TRIM28 and p-mTOR protein expression in indicated tumor xenografts. Data are presented as means ± SD. *P<0.05.

    Journal: Oncology reports

    Article Title: TRIM28 promotes cervical cancer growth through the mTOR signaling pathway.

    doi: 10.3892/or.2018.6235

    Figure Lengend Snippet: Figure 3. TRIM28 enhances cervical cancer cell tumorigenicity. (A) Tumor volumes were measured on the indicated days. (B) At the end of the experiment, the weights were measured. (C) The proliferation index (right) was determined based on the percentage of Ki67-positive cells (left). (D) Western blot analysis of TRIM28 and p-mTOR protein expression in indicated tumor xenografts. Data are presented as means ± SD. *P<0.05.

    Article Snippet: After blocking the endogenous peroxidase with 3% hydrogen peroxide, the sections were washed with Tris-buffered saline (TBS) and then incubated with a primary antibody targeting TRIM28 (Proteintech, Hubei, China) for 1 h at 37 ̊C.

    Techniques: Western Blot, Expressing

    Figure 2. TRIM28 promotes cervical cancer cell proliferation by accelerating the cell cycle. (A) Western blot analysis of TRIM28 protein expression in TRIM28-infected cells and TRIM28 shRNA-infected cells. GAPDH was used as the loading control. (B) Effects of TRIM28 upregulation or downregulation on the proliferation of SiHa or CaSki cells analyzed by the MTT assay. (C) Representative micrographs (left) and quantification (right) of colonies formed by the indicated cervical cancer cell lines. (D) Cell cycle progression of the indicated cervical cancer cell lines analyzed by flow cytometry. (E) Representative images (left) and quantification (right) of BrdU-positive cells in the indicated cervical cancer cell lines. Data are presented as means ± SD. *P<0.05.

    Journal: Oncology reports

    Article Title: TRIM28 promotes cervical cancer growth through the mTOR signaling pathway.

    doi: 10.3892/or.2018.6235

    Figure Lengend Snippet: Figure 2. TRIM28 promotes cervical cancer cell proliferation by accelerating the cell cycle. (A) Western blot analysis of TRIM28 protein expression in TRIM28-infected cells and TRIM28 shRNA-infected cells. GAPDH was used as the loading control. (B) Effects of TRIM28 upregulation or downregulation on the proliferation of SiHa or CaSki cells analyzed by the MTT assay. (C) Representative micrographs (left) and quantification (right) of colonies formed by the indicated cervical cancer cell lines. (D) Cell cycle progression of the indicated cervical cancer cell lines analyzed by flow cytometry. (E) Representative images (left) and quantification (right) of BrdU-positive cells in the indicated cervical cancer cell lines. Data are presented as means ± SD. *P<0.05.

    Article Snippet: After blocking the endogenous peroxidase with 3% hydrogen peroxide, the sections were washed with Tris-buffered saline (TBS) and then incubated with a primary antibody targeting TRIM28 (Proteintech, Hubei, China) for 1 h at 37 ̊C.

    Techniques: Western Blot, Expressing, Infection, shRNA, Control, MTT Assay, Flow Cytometry

    Figure 4. TRIM28 promotes cervical cancer cell proliferation via the mTOR signaling pathway. (A) Western blot analysis of TRIM28, p-mTOR(S2448), mTOR, p-S6K1(T389), and S6K1 in TRIM28 shRNA-infected CaSki cells and TRIM28-infected SiHa cells in the presence or absence of 20 nM evero- limus (EVE) for 48 h. GAPDH served as the loading control. (B-D) Cell proliferation, cell cycle, and BrdU incorporation were analyzed in TRIM28-infected SiHa cells in the presence or absence of EVE for 48 h. Data are presented as means ± SD. *P<0.05.

    Journal: Oncology reports

    Article Title: TRIM28 promotes cervical cancer growth through the mTOR signaling pathway.

    doi: 10.3892/or.2018.6235

    Figure Lengend Snippet: Figure 4. TRIM28 promotes cervical cancer cell proliferation via the mTOR signaling pathway. (A) Western blot analysis of TRIM28, p-mTOR(S2448), mTOR, p-S6K1(T389), and S6K1 in TRIM28 shRNA-infected CaSki cells and TRIM28-infected SiHa cells in the presence or absence of 20 nM evero- limus (EVE) for 48 h. GAPDH served as the loading control. (B-D) Cell proliferation, cell cycle, and BrdU incorporation were analyzed in TRIM28-infected SiHa cells in the presence or absence of EVE for 48 h. Data are presented as means ± SD. *P<0.05.

    Article Snippet: After blocking the endogenous peroxidase with 3% hydrogen peroxide, the sections were washed with Tris-buffered saline (TBS) and then incubated with a primary antibody targeting TRIM28 (Proteintech, Hubei, China) for 1 h at 37 ̊C.

    Techniques: Western Blot, shRNA, Infection, Control, BrdU Incorporation Assay